The field includes orthobiologics, such as platelet-rich plasma (PRP), bone-marrow-derived products, and certain other biological materials. However, evidence varies considerably between treatments and conditions. Some approaches have been studied extensively, while others remain investigational.

The American Academy of Orthopaedic Surgeons (AAOS) describes orthobiologics as biological substances intended to help the body's healing processes and emphasizes the importance of evidence-based evaluation as the field develops.

What Is Regenerative Pain Treatment?

Regenerative pain treatment generally refers to approaches intended to support tissue healing, reduce symptoms, or influence biological processes associated with injury or degeneration.

The term may be used for:

• Platelet-rich plasma injections

• Blood-derived preparations

• Bone-marrow-derived products

• Certain cell-based approaches

• Tissue-based products

• Other investigational biologic therapies

These approaches are not interchangeable. Their preparation, proposed mechanism, evidence, regulatory status, risks, and potential applications can differ substantially.

A treatment described as "regenerative" should therefore be evaluated based on the specific product, procedure, diagnosis, evidence, and regulatory status, rather than the label alone.

Orthobiologics and Pain Management

Orthobiologics are increasingly studied in musculoskeletal medicine.

Potential applications being investigated include:

• Knee osteoarthritis

• Tendon disorders

• Sports-related injuries

• Certain ligament injuries

• Plantar fasciitis

• Some cartilage conditions

• Selected postoperative situations

AAOS notes that orthobiologics are being investigated across a range of musculoskeletal conditions, while also emphasizing continuing evidence gaps.

This means a therapy may show promise for one condition while having insufficient evidence for another.

Platelet-Rich Plasma Injections

Platelet-rich plasma, commonly called PRP, is produced from a patient's blood and concentrates platelets and associated biological factors.

PRP injections have been studied for several musculoskeletal conditions.

For knee osteoarthritis, AAOS guidance indicates that PRP may reduce pain and improve function, but rates the strength of the recommendation as limited because studies have produced variable results and differ in methodology.

PRP preparation can also vary.

Differences may involve:

• Platelet concentration

• White blood cell concentration

• Preparation method

• Injection volume

• Number of injections

• Treatment interval

• Condition being treated

These differences make it difficult to assume that results from one PRP protocol will apply to every treatment.

Other Injection Options

Regenerative pain treatment may involve several types of injectable approaches, but they should not automatically be considered equivalent.

Potential categories include:

PRP

Uses concentrated components derived from the patient's blood.

Bone-marrow-derived products

These may involve aspirated bone marrow and cellular or biological components. Evidence and regulatory considerations vary according to the product and intended use.

Adipose-derived products

Some treatments use materials derived from fatty tissue. Their regulatory status and evidence vary substantially.

Other biologic products

Some clinics may promote products derived from amniotic tissue, umbilical-cord materials, or other biological sources.

The specific product and its regulatory pathway matter considerably when evaluating these treatments.

Regenerative Treatments vs. Conventional Pain Care

Regenerative approaches are generally not a substitute for established rehabilitation and medical care.

Depending on the condition, conventional management may include:

• Physical therapy

• Therapeutic exercise

• Activity modification

• Weight management when appropriate

• Nonoperative medical treatment

• Appropriate pain-management strategies

• Bracing or assistive devices

• Specialist evaluation

• Surgery for selected structural conditions

A comprehensive treatment plan should consider the full range of appropriate options rather than assuming that an injection alone will resolve the underlying problem.

Physical Therapy and Rehabilitation

Rehabilitation remains an important part of managing many musculoskeletal pain conditions.

Physical therapy may focus on:

• Strength

• Mobility

• Flexibility

• Balance

• Movement mechanics

• Joint stability

• Functional activities

• Gradual return to activity

If an injection is being considered, rehabilitation planning may still be relevant before, during, or after the procedure.

The appropriate exercise program depends on the diagnosis, tissue involved, symptoms, physical condition, and professional recommendations.

Recovery Planning After an Injection

Recovery depends on the specific injection and the condition being treated.

A recovery plan may address:

Activity

Temporary changes to strenuous activity may sometimes be recommended.

Rehabilitation

Exercises may be introduced or adjusted according to the treatment plan.

Symptom monitoring

Pain, swelling, mobility, and other symptoms may be monitored after treatment.

Follow-up

The healthcare professional may evaluate whether symptoms and function are changing as expected.

People should follow the specific post-procedure instructions provided by their healthcare team rather than assuming that every regenerative injection has the same recovery requirements.

Evaluating Evidence

One of the most important considerations is the quality of evidence supporting a particular treatment for a particular condition.

Useful questions include:

• What exact condition is being treated?

• What product is being injected?

• What clinical trials support its use?

• What outcomes were measured?

• How long were patients followed?

• Were there appropriate comparison groups?

• Are the results reproducible?

• What risks have been reported?

• Is the product authorized for the intended use?

AAOS has established resources and an orthobiologics registry to improve understanding of long-term safety, effectiveness, and real-world outcomes.

FDA and Regenerative Medicine

In the United States, the FDA regulates regenerative medicine products.

The FDA warns that many products marketed as regenerative therapies are not approved for broad treatment of conditions such as chronic pain or orthopedic disorders. FDA specifically states that unapproved regenerative medicine products may carry serious risks and that inclusion in a clinical-trial database does not itself mean a product is legally marketed or FDA-approved.

This distinction is especially important for products marketed as:

• Stem-cell treatments

• Exosome products

• Amniotic products

• Umbilical-cord products

• Adipose-derived products

• Other cell-based therapies

Patients should verify the regulatory status of a specific product and intended use rather than relying solely on promotional descriptions.

Current Evidence for PRP

Evidence for PRP is condition-specific.

For knee osteoarthritis, AAOS reports that PRP may improve pain and function, but the recommendation remains limited because of differences between studies and uncertainty about factors such as preparation and patient selection.

For other musculoskeletal conditions, evidence may be stronger, weaker, or inconsistent.

A 2026 AAOS symposium emphasized the need for evidence-based evaluation of orthobiologics and continued research into which patients and conditions are most likely to benefit.

Potential Benefits and Limitations

Potential reasons a clinician and patient might consider an orthobiologic approach include:

• Interest in nonsurgical treatment

• Persistent symptoms despite conservative care

• Certain tissue injuries

• Selected musculoskeletal conditions

• Desire to explore evidence-supported alternatives

Important limitations include:

• Evidence varies considerably by condition

• Treatments may not work for everyone

• Product preparation can vary

• Some treatments remain investigational

• Long-term evidence may be limited

• Insurance coverage can vary

• Some products may not be legally marketed for the proposed use

A treatment should therefore be evaluated based on its evidence and regulatory status rather than the term "regenerative" alone.

Risks and Safety Considerations

Injection-based treatments can have risks.

Potential complications may include:

• Pain at the injection site

• Temporary swelling

• Bleeding

• Infection

• Tissue irritation

• Nerve or blood-vessel injury

• Adverse reactions

Risks vary according to the product, injection site, procedure, patient health, and clinical setting.

FDA has reported serious adverse events associated with certain unapproved regenerative medicine products, reinforcing the importance of understanding what product is being administered and whether it is appropriately authorized.

Choosing a Specialist

Depending on the condition, evaluation may involve:

• Orthopedic specialists

• Sports-medicine physicians

• Physical medicine and rehabilitation specialists

• Pain-management physicians

• Rheumatology professionals

• Physical therapists

A qualified professional can help determine whether an injection is appropriate and whether other treatment options should be considered first.

Questions to Ask Before Regenerative Treatment

Before proceeding, patients can ask:

• What diagnosis is being treated?

• What exact product will be used?

• Where is the product sourced from?

• Is the treatment FDA-approved for this use?

• What evidence supports it for my condition?

• What are the potential risks?

• What alternatives are available?

• How many treatments are typically considered?

• What rehabilitation is recommended?

• What recovery restrictions should I expect?

• How will treatment success be measured?

• What happens if symptoms do not improve?

These questions can help distinguish evidence-based care from unsupported marketing claims.

Recent Developments in Regenerative Pain Treatment

Orthobiologic research continues to expand.

Recent developments include:

• Greater research into PRP preparation

• More clinical studies of orthobiologics

• Increased attention to patient selection

• Greater interest in real-world outcomes

• Development of orthobiologics registries

• Improved evidence-monitoring tools

• Research into cell-based therapies

• Greater regulatory scrutiny of unapproved products

In December 2025, AAOS announced its Orthobiologics Registry to track long-term safety, effectiveness, and real-world outcomes for orthobiologic treatments in knee osteoarthritis.

In August 2026, AAOS also convened experts to discuss the evidence gaps and future direction of orthobiologics.

Regenerative Pain Treatment Planning Checklist

Before considering a regenerative or orthobiologic treatment, discuss:

• Confirm the diagnosis

• Identify the specific treatment being proposed

• Review clinical evidence for the condition

• Check regulatory status

• Review potential risks

• Compare conventional treatment options

• Consider physical rehabilitation

• Discuss expected recovery

• Establish treatment goals

• Determine follow-up requirements

• Review what happens if treatment is unsuccessful

• Verify appropriate clinical oversight

Tools and Resources

Useful resources include:

• FDA regenerative medicine resources: Information about regulatory status and consumer safety.

• AAOS Biologics resources: Evidence-based information concerning orthobiologics.

• AAOS Orthobiologics Registry: Real-world outcome tracking for selected treatments.

• Clinical-trial databases: Information about ongoing and completed research studies.

• Orthopedic and rehabilitation specialists: Individualized assessment and treatment planning.

Frequently Asked Questions

1. What is regenerative pain treatment?

Regenerative pain treatment is a broad term used for biological or orthobiologic approaches intended to support tissue healing or modify biological processes associated with pain. Evidence varies considerably between treatments and conditions.

2. What is a PRP injection?

PRP is prepared from a person's blood and contains a concentrated amount of platelets and associated biological factors. PRP has been studied for several musculoskeletal conditions, with evidence varying according to the condition and treatment protocol.

3. Are stem-cell treatments approved for chronic pain?

FDA states that regenerative medicine therapies have not been approved for the treatment of chronic pain or orthopedic conditions such as osteoarthritis, tendonitis, disc disease, back pain, knee pain, or shoulder pain.

4. Does PRP work for every type of pain?

No. Evidence is condition-specific. For example, AAOS reports a limited recommendation for PRP in symptomatic knee osteoarthritis because research findings vary.

5. Is regenerative treatment a replacement for physical therapy?

Not necessarily. Rehabilitation may remain an important part of musculoskeletal care, and injection-based treatment should be evaluated alongside other appropriate treatment approaches.

Conclusion

Regenerative pain treatment is a rapidly developing area of musculoskeletal medicine that includes PRP and other orthobiologic approaches.

The evidence is not uniform across treatments or conditions. Some approaches have encouraging research, while others remain investigational or lack sufficient evidence for routine use.

A thoughtful treatment decision should consider the diagnosis, available evidence, regulatory status, potential risks, rehabilitation needs, alternatives, and individual circumstances.